GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » CytoSorbents Corp (NAS:CTSO) » Definitions » Price-to-Owner-Earnings

CytoSorbents (CytoSorbents) Price-to-Owner-Earnings : (As of Jun. 08, 2024)


View and export this data going back to 2005. Start your Free Trial

What is CytoSorbents Price-to-Owner-Earnings?

As of today (2024-06-08), CytoSorbents's share price is $0.888. CytoSorbents does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for CytoSorbents's Price-to-Owner-Earnings or its related term are showing as below:


CTSO's Price-to-Owner-Earnings is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 31.965
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-06-08), CytoSorbents's share price is $0.888. CytoSorbents's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.59. Therefore, CytoSorbents's PE Ratio for today is At Loss.

As of today (2024-06-08), CytoSorbents's share price is $0.888. CytoSorbents's EPS without NRI for the trailing twelve months (TTM) ended in was $-0.58. Therefore, CytoSorbents's PE Ratio without NRI for today is At Loss.


CytoSorbents Price-to-Owner-Earnings Historical Data

The historical data trend for CytoSorbents's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CytoSorbents Price-to-Owner-Earnings Chart

CytoSorbents Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

CytoSorbents Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of CytoSorbents's Price-to-Owner-Earnings

For the Medical Devices subindustry, CytoSorbents's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CytoSorbents's Price-to-Owner-Earnings Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, CytoSorbents's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where CytoSorbents's Price-to-Owner-Earnings falls into.



CytoSorbents Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

CytoSorbents's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.888/-0.56
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CytoSorbents  (NAS:CTSO) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


CytoSorbents Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of CytoSorbents's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


CytoSorbents (CytoSorbents) Business Description

Traded in Other Exchanges
Address
305 College Road East, Princeton, NJ, USA, 08540
CytoSorbents Corp is involves in the treatment of life-threatening conditions in the intensive care (ICU) and cardiac surgery using blood purification via proprietary polymer adsorption technology. It has a number of products commercialized and in development based on this technology platform.
Executives
Edward Raymond Jones director 70 HOGAN LANE, AMBLER PA 19002
Kathleen P. Bloch officer: Chief Financial Officer 3 PERSHING COURT, NORTH BRUNSWICK NJ 08902
Vincent Capponi officer: Chief Operating Officer MEDASORB TECHNOLOGIES, 7 DEER PARK DRIVE, SUITE K, MONMOUTH JUNCTION NJ 08852
Phillip P. Chan director, officer: President and CEO 1001 BRIGGS ROAD, SUITE 280, MOUNT LAUREL NJ 08054
Efthymios Deliargyris officer: Chief Medical Officer C/O PLX PHARMA,INC.8285 EL RIO STREET, SUITE 210, HOUSTON TX 77054
Jiny Kim director C/O CYTOSORBENTS CORPORATION, 7 DEER PARK DRIVE, SUITE K, MONMOUTH JUNCTION NJ 08852
Alan D. Sobel director 293 EISENHOWER PARKWAY, LIVINGSTON NJ 07039
Michael G. Bator director C/O CYTOSORBENTS CORP., 7 DEER PARK DR., SUITE K, MONMOUTH JUNCTION NJ 08852
Alex D'amico officer: Chief Financial Officer 10 EAST PASSAIC AVENUE, UNIT C-2, NUTLEY NJ 07110
Al Kraus director MEDASORB TECHNOLOGIES, 7 DEER PARK DRIVE, SUITE K, MONMOUTH JUNCTION NJ 08852
Eric R. Mortensen officer: Chief Medical Officer C/O CYTOSORBENTS CORPORATION, 7 DEER PARK DRIVE, SUITE K, MONMOUTH JUNCTION NJ 08852
Njtc Investment Fund, Lp 10 percent owner 1001 BRIGGS ROAD, SUITE 280, MOUNT LAUREL NJ 08054
Robert Shipley 10 percent owner 9 NOBLE ROAD, NOGALES AZ 85621
Ronald Berger officer: See Remarks 7 DEERPARK DRIVE, STE K, MONMOUTH JUNCTION NJ 08852
Thomas Bocchino officer: Chief Financial Officer C/O CYTOSORBENTS CORP., 7 DEER PARK DRIVE, SUITE K, MONMOUTH JUNCTION NJ 08852